Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T11:35:44.771Z.
Calculation as of: 2026-10-06T11:35:44.771Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 58a2fa14633c50703c8ff5f7fcb702de1515a66dae0cc773e6a723eda01f3aaa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$12.89B
EBITDA Yield
9.14%
TTM Avg
9.65%
3Y Avg
7.99%
5Y Avg
6.69%
Market Cap
$13.19B
EBITDA Yield
0.07%
TTM Avg
0.83%
3Y Avg
2.25%
5Y Avg
3.25%
Market Cap
$12.52B
EBITDA Yield
3.39%
TTM Avg
4.26%
3Y Avg
4.90%
5Y Avg
5.03%
Market Cap
$12.17B
EBITDA Yield
4.56%
TTM Avg
3.98%
3Y Avg
4.87%
5Y Avg
4.87%
Market Cap
$12.00B
EBITDA Yield
9.93%
TTM Avg
10.04%
3Y Avg
12.07%
5Y Avg
11.92%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | N/A | N/A | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 9.14% | 9.65% | 7.99% | 6.69% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.07% | 0.83% | 2.25% | 3.25% |
| Baxter International Inc. (BAX)vs › | $12.52B | 3.39% | 4.26% | 4.90% | 5.03% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 1.64% | 1.61% | 1.04% | 0.84% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 4.56% | 3.98% | 4.87% | 4.87% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 9.93% | 10.04% | 12.07% | 11.92% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 1.07% | 0.36% | 0.36% | 0.36% |
| DaVita Inc. (DVA)vs › | $11.47B | 13.06% | 11.31% | 11.13% | 11.02% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 3.07% | 2.49% | 2.88% | 2.79% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
